Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial - 01/10/24
, Maximilian Hochmair, MD b, Ji-Youn Han, MD PhD c, Noemi Reguart, MD PhD d, e, Pierre-Jean Souquet, MD f, Egbert F Smit, MD PhD g, Sergey V Orlov, MD PhD h, Johan Vansteenkiste, MD PhD i, Makoto Nishio, MD PhD j, Maja de Jonge, MD PhD k, Wallace Akerley, MD l, m, Edward B Garon, MD n, Harry J M Groen, MD PhD o, Daniel S W Tan, MD PhD p, Takashi Seto, MD q, Garrett M Frampton, PhD r, Anna Robeva, MS s, Mariana Carbini, MD t, Sylvie Le Mouhaer, MSc u, Alejandro Yovine, MD t, Aislyn Boran, PhD v, Claudia Bossen, PhD t, Yiqun Yang, PhD s, Lexiang Ji, PhD w, Lauren Fairchild, PhD w, Rebecca S Heist, MD xSummary |
Background |
Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes from the phase 2 GEOMETRY mono-1 study with an aim to provide further evidence for the activity of capmatinib.
Methods |
In this non-randomised, multi-cohort, open-label, phase 2 trial conducted in 152 centres and hospitals in 25 countries, with patients treated in 95 centres in 20 countries, eligible patients (aged ≥18 years) with MET-dysregulated, EGFR wild-type, and ALK rearrangement-negative advanced NSCLC (stage IIIB/IV) and an Eastern Cooperative Oncology Group performance status of 0 or 1 were assigned to cohorts (1a, 1b, 2, 3, 4, 5a, 5b, 6 and 7) based on their MET status (METex14 or MET amplification) and previous therapy lines. Patients received capmatinib (400 mg orally twice daily) in 21-day treatment cycles. The primary endpoint was overall response rate by blinded independent central review per Response Evaluation Criteria in Solid Tumours version 1.1 and was performed on the full analysis set (all patients who received at least one dose of capmatinib). Previous reports of this study had published interim or primary data for cohorts 1–7. Here, we report the final clinical outcomes from all METex14 cohorts (4, 5b, 6, and 7) and safety from all study cohorts (1–7). The trial is registered with ClinicalTrials.gov, NCT02414139, and has been completed.
Findings |
Of 373 treated patients enrolled from June 11, 2015, to March 12, 2020, 160 (97 [61%] female) patients had METex14 NSCLC and were enrolled in four cohorts: 60 treatment-naive (cohorts 5b and 7) and 100 previously treated (cohorts 4 and 6). The overall median study follow-up was 46·4 months (IQR 41·8–65·4) for the treatment-naïve patients and 66·9 months (56·7–73·9) for previously treated patients, respectively. Overall responses were recorded in 41 (68%; 95% CI 55·0–79·7) of 60 treatment-naive patients and 44 (44%; 95% CI 34·1–54·3) of 100 previously treated patients. In all 373 treated patients, the most common treatment-related adverse events were peripheral oedema (n=174; 47%), nausea (n=130; 35%), increased blood creatinine (n=78; 21%), and vomiting (n=74; 20%). Grade 3–4 serious adverse events occurred in 164 (44%) patients, dyspnoea being the most common (18 patients [5%]). Treatment-related deaths occurred in four (1%) patients (one each of cardiac arrest, hepatitis, organising pneumonia, and pneumonitis). No new safety signals were reported.
Interpretation |
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for treatment-naive and previously treated patients with METex14 NSCLC.
Funding |
Novartis Pharmaceuticals.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 10
P. 1357-1370 - octobre 2024 Retour au numéro
Article précédent
- Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
- Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Wenhua Liang, Jianxing He
- Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
- Sudha Sundar, Ridhi Agarwal, Clare Davenport, Katie Scandrett, Susanne Johnson, Partha Sengupta, Radhika Selvi-Vikram, Fong Lien Kwong, Sue Mallett, Caroline Rick, Sean Kehoe, Dirk Timmerman, Tom Bourne, Ben Van Calster, Hilary Stobart, Richard D Neal, Usha Menon, Alex Gentry-Maharaj, Lauren Sturdy, Ryan Ottridge, Jon Deeks, ROCkeTS collaborators, Robert Kent, Natalia Rosello, Vivek Malhotra, Karen Jermy, Tim Duncan, Victoria Ames, Aarti Sharma, Anju Sinha, Majmudar Tarang, Mackenzie Ciara, Neil Hebblethwaite, Kendra Exley, Robert Macdonald, Marianne Harmer, Tracey Hughes, Rob Parker, Ahmed Darwish, Parveen Abedin, Moji Balogun, Bruce Ramsay, Roger Moshy, Mark Roberts, Michelle Russell, Ahmad Sayasneh, Ahmed Abdelbar, Shahram Abdi, Julia Palmer, Ketankumar Gajjar, Dominic Blake, Adam Naskretski, Fateh Ghazal, Harinder Rai, Patrick Keating, Nicholas Wood, Chellappah Gnanachandran, Hafez Alawad, Sonali Kaushik, Sonali Baron, Lavanya Vita, Hans Nagar, Ranjit Manchanda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?